What Happened

Viking Therapeutics, a clinical-stage biotech with a market cap of $3.59B, is speculated to be acquired due to its advanced obesity asset, VK2735. Analysts rate it a Buy with a target price of $92.33, driven by promising Phase 3 results.

Who Is Affected

Pfizer, Eli Lilly, Novo Nordisk, and Structure Therapeutics are key players in the obesity drug market. Viking's acquisition could impact their strategic positioning and market share.

Market Impact

• Potential re-rating of the obesity small-cap basket
• Validation of the tuck-in acquisition playbook
• Secondary winner Structure Therapeutics could inherit scarcity premium

What to Watch

Monitor Phase 3 enrollment updates, oral VK2735 progress, and any Big Pharma business development signaling through 2026. These indicators will provide insights into the likelihood of an acquisition.